Promosyon programı Ascendis Pharma A/S
Gelişmiş program
Basit grafik
Şirket hakkında Ascendis Pharma A/S
Ascendis Pharma A / S, биофармацевтическая компания, разрабатывает терапевтические препараты для неудовлетворенных медицинских потребностей. Компания разрабатывает гормон роста TransCon, который завершил III фазу клинических испытаний дефицита гормона роста. Он также разрабатывает паратиреоидный гормон TransCon для лечения гипопаратиреоза взрослых; и TransCon CNP для ахондроплазии. daha fazla ayrıntıIPO date | 2015-01-28 |
---|---|
ISIN | US04351P1012 |
Industry | Biotechnology |
Sector | Health Care |
Валюта | usd |
Валюта отчета | eur |
Сайт | https://ascendispharma.com |
Цена ао | 151.53 |
Günlük fiyat değişimi: | +0.7127% (151.53) |
---|---|
Haftalık fiyat değişimi: | -1.27% (154.58) |
Aylık fiyat değişimi: | +17.96% (129.37) |
3 ayda fiyat değişimi: | +11.95% (136.315) |
Altı ayda fiyat değişimi: | +13.31% (134.68) |
Yıllık fiyat değişimi: | +0.0918% (152.47) |
3 yılda fiyat değişimi: | +48.9% (102.49) |
5 yılda fiyat değişimi: | +8.23% (141.01) |
10 yılda fiyat değişimi: | 0% (152.61) |
Yılbaşından bu yana fiyat değişimi: | +10.85% (137.67) |
|
Hafife alma
|
Yeterlik
|
|||||||||||||||||||||||||||||||||||||
Temettüler
|
Görev
|
Büyüme dürtüsü
|
Kurumlar | Hacim | Paylaşmak, % |
---|---|---|
Artisan Partners Limited Partnership | 6 | 9.74 |
FMR, LLC | 5 | 8.48 |
Westfield Capital Management Co LP | 4 | 7 |
Avoro Capital Advisors LLC | 4 | 6.81 |
Janus Henderson Group PLC | 4 | 6.47 |
Wellington Management Group, LLP | 3 | 4.72 |
T. Rowe Price Investment Management, Inc. | 3 | 4.41 |
Capital International Investors | 2 | 3.76 |
Franklin Resources, Inc. | 2 | 3.4 |
Price (T.Rowe) Associates Inc | 2 | 3.06 |
ETF | Paylaşmak, % | Yıllık karlılık, % | Temettüler, % |
---|---|---|---|
Harbor Health Care ETF | 15.049 | 19.98 | 1.85 |
Harbor Disruptive Innovation ETF | 1.94674 | 29.05 | 0.39896 |
Virtus LifeSci Biotech Products ETF | 1.73873 | 36.79 | 0.13953 |
American Century Focused Dynamic Growth ETF | 1.00544 | 51.92 | 0.16246 |
Invesco Nasdaq Biotechnology ETF | 0.8571 | 28.58 | 0.8565 |
Simplify Health Care ETF | 0.85284 | 27.81 | 1.00373 |
Future Tech ETF | 0.85005 | 426.34 | 0.8416 |
Principal Healthcare Innovators ETF | 0.85005 | 618.5 | 0.8416 |
ProShares UltraShort Nasdaq Biotechnology | 0.77 | -40.36 | 1.76 |
Northern Lights Fund Trust IV | 0.69803 | 42.1 | 0.49246 |
ProShares Ultra Nasdaq Biotechnology | 0.57302 | 51.7 | 0.85651 |
Putnam Sustainable Future ETF | 0.48877 | 32.87 | 0.70689 |
First Trust Nasdaq BuyWrite Income ETF | 0.19858 | 7.27 | 0.92977 |
![]() |
0.02162 | 5.29 | 3.28401 |
PIMCO RAFI Dynamic Multi-Factor International Equity ETF | 0.01902 | 12.12 | 3.49094 |
Fidelity Blue Chip Growth ETF | 0.01204 | 39.34 | 0.54012 |
Süpervizör | İş unvanı | Ödeme | Doğum yılı |
---|---|---|---|
Mr. Jan Moller Mikkelsen | President, CEO, Member of Executive Board & Executive Director | N/A | 1960 (65 yıllar) |
Mr. Michael Wolff Jensen L.L.M. | Executive VP, Chief Legal Officer & Member of the Executive Board | N/A | 1971 (54 yıl) |
Mr. Scott T. Smith | CFO, Executive VP & Member of Executive Board | N/A | 1974 (51 yıl) |
Ms. Lotte Sonderbjerg | Executive VP, Chief Administrative Officer & Member of the Executive Board | N/A | 1961 (64 yıl) |
Mr. Flemming Steen Jensen | Executive Vice President of Product Supply & Quality | N/A | 1961 (64 yıl) |
Mr. Timothy J. Lee | Senior Director of Investor Relations | N/A | |
Dr. Kennett Sprogoe Ph.D. | Executive VP and Head of Research & Product Development | N/A | 1979 (46 yıllar) |
Mr. Mads Bodenhoff | Senior VP of Finance & Principal Accounting Officer | N/A | |
Dr. Stina Singel M.D., Ph.D. | Executive VP & Head of Clinical Development for Oncology | N/A | 1974 (51 yıl) |
Mr. Joseph Kelly | Head of U.S. Commercial of Endocrinology | N/A | 1969 (56 yıllar) |
Adres: Denmark, Hellerup, Tuborg Boulevard 12 - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://ascendispharma.com
Web sitesi: https://ascendispharma.com